Large arrow graphic

inVentiv Health Spotlights Patient-Centered Innovations with the Potential to Accelerate Drug Delivery at Biotech Showcase

Event Panels to Discuss Value of Real-World Evidence (RWE) and Digital Medicine

BURLINGTON, Mass., January 8, 2017 – inVentiv Health, a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market, will moderate two panels during this year’s Biotech Showcase. Panels will spotlight patient-centered trial design and technology innovations that have the potential to improve the development and delivery of medicines. Biotech Showcase runs parallel to the J.P. Morgan Healthcare conference in San Francisco.

Both real-world evidence and digital medicine have the ability to impact the industry’s most pressing challenge, to accelerate the delivery of therapies to patients most in need. inVentiv Health shares unique perspectives on these topics based on the company’s purpose-built business model, combining a leading Clinical Research Organization (CRO) with the industry’s first Contract Commercial Organization (CCO).

“At inVentiv we have a broad overview across clinical to commercial – from lab to life. This comprehensive approach gives us the ability to address complex industry challenges by designing integrated solutions,” said Michael Bell, Chairman and Chief Executive Officer of inVentiv Health. “By bringing together clinical and commercial experts, we can enhance clinical trial design and launch strategies to optimize market access.”

The Real-World Evidence Panel will be hosted by David Thompson Ph.D., Senior Vice President for Real-World Evidence Consulting, inVentiv Health. Thompson is an economist with nearly 30 years of experience in the health economics arena. He also has served for the past ten years as Editor-in-Chief for Value & Outcomes Spotlight, a health economics publication devoted to policy and methodologic issues in real-world evidence generation. Lita Sands, Managing Director of Digital Transformation, inVentiv Health, will host the Digital Medicine Panel. Sands has more than 20 years of experience in digital and multi-channel marketing, counseling both biopharma and professional service organizations. Her expertise includes leveraging digital engagement and advanced analytics.

Panel Details

The Real-World Evidence Revolution: Finding Value and Relevance Through the Stakeholder Perspective [Mon, Jan 9, 12:00 p.m. – 1:45 p.m. PST, Hilton Union Square, San Francisco]

This session will discuss how real-world insights from patients and other stakeholders can lead to better drug development, improved patient compliance and ultimately better outcomes. The panel will be moderated by David Thompson. Panel participants include:

  • Wade Ackerman, Partner, Covington & Burling LLP
  • Ted Haack, VP, LatticePoint Consulting
  • Jamie Heywood, Co-Founder and Chairman, PatientsLikeMe
  • Philippe Lopes-Fernandes, Senior Vice President, Global Head, Business Development and Alliance Management, EMD Serono
  • Steve Wooding, Head, Global Commercial Strategy Organization, the Janssen Pharmaceutical Companies of Johnson & Johnson

Digital Medicine: Where Are We Now? [Tue, Jan 10, 4:00 p.m. – 4:55 p.m. PST, Parc 55, San Francisco]

This panel will highlight today’s hottest technologies in the digital medicine space designed to improve disease management, adherence and patient engagement. The panel will be moderated by Lita Sands. Panel participants include:

  • Deborah Kilpatrick, CEO, Evidation Health
  • Corey McCann, CEO, Pear Therapeutics
  • Aaron Nelson, General Partner, dRx Capital
  • Kal Patel, Senior Vice President, Digital Health, Flex

To learn more about how inVentiv Health experts can help you, please contact us by clicking here.

Contact Us

inVentiv Health has been made aware of an internet scam targeting job seekers who have posted their resumes on job posting websites. Scammers are contacting applicants via email and purporting to represent inVentiv Health. Many of these scammers are using Gmail accounts and Google Hangouts to communicate with applicants. All correspondence with us comes from an internal employee with a valid email address. Anyone who suspects they have been solicited in this scam should contact the FBI at